<DOC>
	<DOCNO>NCT02749721</DOCNO>
	<brief_summary>The purpose study explore pattern Brain Network Activation ( BNA ) change baseline endpoint 1 ) efficacy core symptom Major Depressive Disorder ( MDD ) 2 ) improvement cognitive dysfunction acute treatment flexible dose vortioxetine adult outpatient MDD subjective complaint cognitive dysfunction .</brief_summary>
	<brief_title>The Relationship Among Changes Brain Network Activation Adult Outpatients With Major Depressive Disorder</brief_title>
	<detailed_description>Vortioxetine novel antidepressant hypothetical multimodal mechanism action . It think work combination multiple pharmacological mode action : 5-HT ( hydroxytryptamine , serotonin ) reuptake inhibition , 5-HT3 ( hydroxytryptamine , serotonin ) 5-HT7 ( hydroxytryptamine , serotonin ) receptor antagonism , 5-HT1A ( hydroxytryptamine , serotonin ) receptor agonism , 5-HT1B ( hydroxytryptamine , serotonin ) receptor partial agonism . In vivo nonclinical study demonstrate vortioxetine enhances level neurotransmitter 5-HT ( hydroxytryptamine , serotonin ) , norepinephrine ( NE ) , dopamine ( DA ) , acetylcholine histamine specific area brain . These affinity consider clinical relevance involve mechanism action therapeutic dos . Vortioxetine show improve core depressive symptom improve cognitive function adult outpatient MDD subjective complaint cognitive function . This pilot study intend evaluate extent BNA technology provide clinically valuable information provide information toward design subsequent confirmatory study elucidate effect vortioxetine MDD cognitive function population . This exploratory study ascertain acute change core depression symptom , cognitive function , tolerability , safety use flexible-dose vortioxetine adult outpatient MDD subjective complaint cognitive functioning , measure BNA change standard outcome measure depression cognition . The study consist 8 week open-label treatment MDD response treatment measure standard research depression scale BNA electroencephalogram ( EEG ) read take certain point trial . An important aim study explore correlation may exist change measure brainwave pattern report change depressive symptom</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>The subject single episode recurrent MDD ( acute onset recurrence recurrent MDD poor interepisode recovery ) ( interepisode period meet full MDD criterion ) primary diagnosis accord DSMIVTR criterion . The current major depressive episode ( MDE ) confirm use Mini International Neuropsychiatric Interview ( MINI V6.0.0 ) . The subject MADRS total score ≥26 . Subject report subjective cognitive dysfunction ( difficulty concentrating , slow thinking , difficulty learn new thing remember thing ) . The report duration current MDE least 3 month longer 24 month . The subject man woman 18 65 year old , inclusive . Righthanded , normal ( correct ) vision , normal hearing . The subject score ≥70 Digit Symbol Substitution Test ( DSST ) Baseline Visit . Failure respond inability tolerate adequate trial vortioxetine past . Exposure investigational compound 30 day prior enrollment Exposure psychoactive otherwise exclude medication within five halflives baseline visit study . Excluded medication include : antidepressant , anxiolytic , anticonvulsant , barbiturate , chloral hydrate , lithium , antipsychotic , benzodiazepine , hypnotic , monoamine oxidase inhibitor ( MAOIs ) , muscle relaxer , triptans , centrallyacting antihistamine , central alpha2 agonist , decongestant , psychostimulants , dopamine agonist , opioid pain medication , oral corticosteroid , Lmethylfolate , Sadenosyl methionine ( SAMe ) , 5HTP ( hydroxytryptophan ) , St. John 's Wort , The subject 1 following : Primary psychiatric disorder MDD define Diagnostic Statistical Manual Mental Disorders 4 Text Revision ( DSMIVTR ) ( assess MINI , Version 6.0.0 ) . Current history attention deficit hyperactivity disorder ( ADHD ) , pervasive developmental disorder , manic hypomanic episode , schizophrenia , psychotic disorder , include major depression psychotic feature , mental retardation , organic mental disorder , mental disorder due general medical condition define DSMIVTR . Current diagnosis alcohol substance abuse dependence ( exclude nicotine caffeine ) define DSMIVTR sustain full remission least 6 month ( abuse ) 12 month ( dependence ) prior Screening . Positive urine drug screen prior Baseline . Presence history clinically significant neurological disorder ( include epilepsy ) . Neurodegenerative disorder ( Alzheimer Disease , Parkinson Disease , multiple sclerosis , Huntington Disease , etc ) . Any unstable medical condition determine principal investigator ( PI ) . Any DSMIV Axis II disorder might compromise study determine PI . The subject disorder treatment take priority treatment MDD likely interfere study treatment impair treatment compliance . The subject physical , cognitive , language impairment severity adversely affect validity data derive neuropsychological test . The subject significant risk suicide accord PI 's clinical judgment . The subject , opinion PI , pose risk harm others . The subject initiate formal cognitive behavioral therapy , systemic psychotherapy within less 6 month study screening , plan initiate therapy study . The subject receive electroconvulsive therapy , vagus nerve stimulation , repetitive transcranial magnetic stimulation within 12 month prior Screening . The current MDE consider PI resistant 2 adequate antidepressant treatment least 6 week duration recommend dose . The subject pregnant breastfeeding , intend become pregnant , , within 30 day participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>depression</keyword>
	<keyword>brain network activation</keyword>
	<keyword>vortioxetine</keyword>
</DOC>